HC Wainwright Has Positive Forecast for BioAtla Q1 Earnings

BioAtla, Inc. (NASDAQ:BCAB) – Analysts at HC Wainwright upped their Q1 2025 earnings estimates for BioAtla in a research report issued on Monday, March 31st. HC Wainwright analyst A. He now anticipates that the company will post earnings of ($0.28) per share for the quarter, up from their prior estimate of ($0.33). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for BioAtla’s Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.44) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.85) EPS.

BioAtla Stock Down 3.9 %

NASDAQ:BCAB opened at $0.34 on Thursday. The company has a market cap of $16.41 million, a PE ratio of -0.20 and a beta of 1.19. The business’s 50 day moving average is $0.40 and its two-hundred day moving average is $1.10. BioAtla has a 52 week low of $0.24 and a 52 week high of $4.02.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08.

Institutional Investors Weigh In On BioAtla

Institutional investors and hedge funds have recently made changes to their positions in the company. Anson Funds Management LP bought a new stake in BioAtla during the fourth quarter valued at $2,720,000. Acorn Capital Advisors LLC acquired a new position in shares of BioAtla in the 4th quarter valued at about $2,384,000. Highbridge Capital Management LLC bought a new stake in shares of BioAtla during the 4th quarter valued at about $1,484,000. Tang Capital Management LLC grew its position in shares of BioAtla by 57.2% during the 4th quarter. Tang Capital Management LLC now owns 1,374,076 shares of the company’s stock valued at $812,000 after buying an additional 500,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in BioAtla by 62.2% during the fourth quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock worth $490,000 after acquiring an additional 318,196 shares during the period. 77.23% of the stock is owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.